Prometheus Biosciences, Inc. (RXDX) financial statements (2022 and earlier)

Company profile

Business Address 9410 CARROLL PARK DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments257,254279,116304,389311,231
Cash and cash equivalents257,254279,116304,389311,231
Receivables1,079679217973
Prepaid expense1,2181,5522,177396
Other undisclosed current assets5,8325,7614,8066,020
Total current assets:265,383287,108311,589318,620
Noncurrent Assets
Property, plant and equipment1,4471,3621,109913
Other undisclosed noncurrent assets971468468468
Total noncurrent assets:2,4181,8301,5771,381
TOTAL ASSETS:267,801288,938313,166320,001
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,9875,4555,0704,558
Accounts payable1,1531,6632,2502,082
Accrued liabilities456481422873
Employee-related liabilities5,3783,3112,3981,603
Deferred revenue3,6683,5612,6862,418
Debt  7,396 
Disposal group, including discontinued operation193475233233
Other undisclosed current liabilities5,5945,6022,3131,578
Total current liabilities:16,44215,09317,6988,787
Noncurrent Liabilities
Long-term debt and lease obligation   7,365
Long-term debt, excluding current maturities   7,365
Liabilities, other than long-term debt16,20411,74513,0403,650
Deferred revenue16,20411,74513,0403,650
Total noncurrent liabilities:16,20411,74513,04011,015
Total liabilities:32,64626,83830,73819,802
Stockholders' equity
Stockholders' equity attributable to parent235,155262,100282,428300,199
Common stock4444
Additional paid in capital424,492421,519414,514413,286
Accumulated deficit(189,341)(159,423)(132,090)(113,091)
Total stockholders' equity:235,155262,100282,428300,199
TOTAL LIABILITIES AND EQUITY:267,801288,938313,166320,001

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
Revenues1,0371,006326760
Gross profit:1,0371,006326760
Operating expenses(30,981)(27,799)(19,172)(12,980)
Operating loss:(29,944)(26,793)(18,846)(12,220)
Nonoperating income (expense)26(540)(153)(1,725)
Investment income, nonoperating26273718
Interest and debt expense (554)(190)(658)
Net loss:(29,918)(27,887)(19,189)(14,603)
Other undisclosed net income attributable to parent 554190658
Net loss available to common stockholders, diluted:(29,918)(27,333)(18,999)(13,945)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
Net loss:(29,918)(27,887)(19,189)(14,603)
Comprehensive loss, net of tax, attributable to parent:(29,918)(27,887)(19,189)(14,603)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: